It commonly occurs in people with CKD because their kidneys do not produce enough erythropoietin (EPO), a hormone that helps regulate production of red blood cells. Cambridge, MA 02142, +1 617.871.2098  phone +1 617.871.2099  fax, Akebia Reports Third Quarter 2020 Financial Results and Recent Business Updates. While the PRO2TECT data showed that vadadustat achieved both the primary and key secondary efficacy endpoints, it did not meet the program's primary safety endpoint for patients not on dialysis, and we remain appropriately cautious in our outlook for potential approval of vadadustat in patients not on dialysis. Créanciers Commerciaux. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Following the recent earnings report, the consensus from eight analysts covering Akebia Therapeutics is for revenues … Akebia Therapeutics, Inc., is looking for an experienced hands-on Associate Director, Revenue/General Accounting who is an enthusiastic, strong leader with a solid revenue accounting background. Losses are predicted to fall substantially, shrinking 69% to US$0.92. Revenues: Total revenue was $60.0 million for the third quarter of 2020 compared to $92.0 million for the third quarter of 2019. Delayed quotes by Sungard. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. For more information, please visit our website at www.akebia.com, which does not form a part of this release. Importantly, we believe the PRO2TECT data will not adversely impact the potential approvability of vadadustat for the treatment of anemia due to CKD in adult patients on dialysis.". About Akebia TherapeuticsAkebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The company has topped consensus revenue estimates two times over the last four quarters. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Akebia plans to submit a New Drug Application (NDA) to the FDA for vadadustat as early as possible in 2021 for two indications: (1) the treatment of anemia due to CKD in adult patients on dialysis, and (2) the treatment of anemia due to CKD in adult patients not on dialysis. It is classified as operating in the Physical, Occupational & Speech Therapists & Audiologists industry. Too much information and not sure what to do? DSE-US-0063. Other risks and uncertainties include those identified under the heading "Risk Factors" in Akebia's Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 and other filings that Akebia may make with the U.S. Securities and Exchange Commission in the future. For 32 years, our Strong Buy list has averaged returns more than twice the market. © 2020 Akebia Therapeutics. The Cambridge, Massachusetts-based company said it had a loss of 42 cents per share. Akebia Therapeutics Q3 Revenue $60 Million. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. Akebia Therapeutics Revenu Net - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Aug 2020. Revenues: Total revenue was $60.0 million for the third quarter of 2020 compared to $92.0 million for the third quarter of 2019. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Akebia Therapeutics 's estimated annual revenue is currently $235M per year. Visit www.zacksdata.com to get our data and content for your mobile app or website. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. The trailing twelve month Revenue of Akebia Therapeutics, Inc. (NASDAQ:AKBA) is reported at 308.2 Million with income of -390900000. IMPORTANT U.S. SAFETY INFORMATION FOR AURYXIA® (ferric citrate) CONTRAINDICATIONAURYXIA® (ferric citrate) is contraindicated in patients with iron overload syndromes, e.g., hemochromatosis. About VadadustatVadadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor designed to mimic the physiologic effect of altitude on oxygen availability. Revenues: Total revenue was $90.1 million for the second quarter of 2020 compared to $100.8 million for the second quarter of 2019. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 23 cents per share. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. This includes personalizing content and advertising. Taking a look at stock we notice that its last check on previous day was $3.58 and 5Y monthly beta was reading 1.89 with its price kept floating in the range of $3.2900 and $3.6000 on the day. The current consensus EPS estimate is -$0.36 on $62.72 million in revenues for the coming quarter and -$2.31 on $309.46 million in revenues for the current fiscal year. Vadadustat is Akebia's investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) in development for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis and not on dialysis. Get the detailed quarterly/annual income statement for Akebia Therapeutics, Inc. (AKBA). See its 7 best stocks FREE. These forward-looking statements (except as otherwise noted) speak only as of the date of this press release, and Akebia does not undertake, and specifically disclaims, any obligation to update any forward-looking statements contained in this press release. Following the recent earnings report, the consensus from eight analysts covering Akebia Therapeutics is for revenues of US$240.2m in 2021, implying a stressful 22% decline in sales compared to the last 12 months. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Anemia due to CKD can have a profound impact on a person's quality of life as it can cause fatigue, dizziness, shortness of breath and cognitive dysfunction. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Comprenez le tableau de financement de AKEBIA THERAPEUT.DL-00001 (AX9.F), découvrez l’origine des fonds et les dépenses de la société. Pe Prix À Revenus. Akebia Therapeutics Fast Facts Akebia Therapeutics's annual revenues are $10-$50 million (see exact revenue data) and has 100-500 employees. Akebia Therapeutics, which belongs to the Zacks Medical - Drugs industry, posted revenues of $59.99 million for the quarter ended September 2020, missing the Zacks Consensus Estimate by … A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. CAMBRIDGE, Mass., Nov. 18, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it ranked number 10 on Deloitte's Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies … ZacksTrade and Zacks.com are separate companies. This was an important milestone for our vadadustat development program, and we remain on track to submit an NDA to the FDA as early as possible next year. A quarter ago, it was expected that this kidney disease treatment developer would post a loss of $0.46 per share when it actually produced a loss of $0.44, delivering a surprise of 4.35%. The call will also be webcast LIVE and can be accessed via the Investors section of the Company's website at http://ir.akebia.com. The insider ownership for the shares of Akebia … Zacks Equity Research So, the shares are expected to perform in line with the market in the near future. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. Akebia Therapeutics, Inc. estimates its current quarter revenue will rise +49.4%, while the growth in revenue is estimated to hit 31.9% for the next quarter. Frais De Vente Et D'Administration. http://www.prnewswire.com/news-releases/akebia-reports-third-quarter-2020-financial-results-and-recent-business-updates-301167158.html, Note Regarding Forward Looking Statements, In October, the Company presented data from its global Phase 3 program at, In August, the Company announced the launch of vadadustat in, In July, the Company announced an investigator-sponsored research study by. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. These data were clear and consistent, and showed that vadadustat achieved both the primary and key secondary efficacy endpoints, as well as the primary and key secondary safety endpoints of the program for patients on dialysis. NYSE and AMEX data is at least 20 minutes delayed. We use cookies to understand how you use our site and to improve your experience. Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, today reported financial results for the third quarter ended September 30, 2020 and provided business updates, including confirming completion of a pre-NDA meeting with the U.S. Food and Drug Administration (FDA) for vadadustat. ADVERSE REACTIONSMost common adverse reactions with AURYXIA were: To report suspected adverse reactions, contact Akebia Therapeutics at 1-844-445-3799. CAMBRIDGE, Mass., Nov. 5, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, today reported financial results for the third quarter ended September 30, 2020 and provided business updates, including confirming completion of a pre-NDA meeting with the U.S. Food and Drug Administration (FDA) for vadadustat. Vadadustat recently completed its global Phase 3 development program for the treatment of anemia due to CKD. A key component of this NDA is the positive data from our global Phase 3 INNO2VATE program for the treatment of anemia due to CKD in adult patients on dialysis, which we shared most recently at ASN Kidney Week. At higher altitudes, the body responds to lower oxygen availability with stabilization of hypoxia-inducible factor, which can lead to increased red blood cell production and improved oxygen delivery to tissues. Forward-Looking StatementsStatements in this press release regarding Akebia's strategy, plans, prospects, expectations, beliefs, intentions and goals are forward-looking statements within the meaning of the U.S. Real time prices by BATS. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. Year-over-year growth is forecast to reach -13.9% down from the last financial year. Akebia's revenue grew 21,724% during the period from 2016 to 2019. Together with our collaborator, Otsuka, we look forward to bringing this innovative therapy to patients on dialysis globally, if approved. Ahead of this earnings release, the estimate revisions trend for Akebia Therapeutics was mixed. Vadadustat is not approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority with the exception of Japan's Ministry of Health, Labour and Welfare (MHLW). the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Start here. Le Chiffre D'Affaires De Vente. November 05, 2020. Akebia Therapeutics's Annual Report & Profile shows critical firmographic facts: A recent pick, Maxar, skyrocketed +178.7% in 3 months. About Anemia due to Chronic Kidney Disease (CKD) Anemia is a condition in which a person lacks enough healthy red blood cells to carry adequate oxygen to the body's tissues. Investor Contact:Kristen K. Sheppard, Esq.ir@akebia.com, (in thousands, except share and per share data), Weighted-average number of common shares - basic and diluted, Cash, cash equivalents and available for sale securities, View original content to download multimedia:http://www.prnewswire.com/news-releases/akebia-reports-third-quarter-2020-financial-results-and-recent-business-updates-301167158.html, Akebia Therapeutics, Inc. The terms "believe," "confident," "expect," "look forward," "on track," "plan," "potential," "will," "working" and similar references are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Private Securities Litigation Reform Act of 1995, as amended, including but not limited to statements regarding the potential for obtaining approval of vadadustat in dialysis and the potential for vadadustat to be a new oral standard of care in dialysis; the potential indications for and benefits of vadadustat; submitting filings for marketing approval of vadadustat, and the timing thereof; the market and clinical opportunity for vadadustat; the belief that the PRO2TECT data will not adversely impact the potential approvability of vadadustat for the treatment of anemia due to CKD in adult patients on dialysis; the expectation regarding the Company's cash resources; and the timing of our cash runway in relation to the expected timing of the U.S. launch of vadadustat. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. This compares to year-ago revenues of $91.98 million. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Valeur Prix Graphique Historique Gains Rendement Du Dividende - AKBA Akebia Therapeutics Le Revenu D'Intérêts - 8/10/2020. Its products include Switch CONNECT and Switch SAFE. To listen to the conference call, please dial (877) 458-0977 (domestic) or (484) 653-6724 (international) using conference ID number 2860285. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms and Conditions of Service. Akebia Therapeutics, which belongs to the Zacks Medical - Drugs industry, posted revenues of $59.99 million for the quarter ended September 2020, missing the Zacks Consensus Estimate by 21.20%. Akebia Therapeutics - Prix De L'Action. Akebia Therapeutics, Inc. (AKBA) - free report >>. Akebia Therapeutics shares have lost about 59.3% since the beginning of the year versus the S&P 500's gain of 6.6%. Créances Commerciales. Each of the company logos represented herein are trademarks of Verizon Media; Microsoft Corporation; Nasdaq, Inc.; Dow Jones & Company; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. If you wish to go to ZacksTrade, click OK. Before this latest report, the consensus had been expecting revenues of US$276.6m and US$0.83 per share in … ", Butler continued, "The pre-NDA meeting also allowed us the opportunity to clarify key questions regarding data from PRO2TECT, our global Phase 3 program for the treatment of anemia due to CKD in adult patients not on dialysis, and we look forward to working with the FDA in their review of these data. Consultez le graphique AKEBIA THERAPEUTICS INC en direct pour suivre l'évolution des cours de ses actions. Can Industrial REITs Make the Most Out of Cyber Monday? Graphique Quotes ... Revenu Net. While Akebia Therapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? To learn more, click here. (AP) _ Akebia Therapeutics Inc. (AKBA) on Thursday reported a loss of $60 million in its third quarter. Akebia Therapeutics (AKBA Quick QuoteAKBA - Free Report) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.23. Akebia Therapeutics, Inc. (NASDAQ:AKBA) concluded the trading on Wednesday, Oct 21, with a fall of -7.96% from its closing price on previous day. Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™ November 16, 2020. Switch, Inc. (Nevada) engages in the provision of technology infrastructure. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Akebia EPS misses by $0.19, misses on revenue. This compares to loss of $0.28 per share a year ago. "Subject to regulatory review and approval, we believe vadadustat has the potential to be a new oral standard of care to help address the unmet needs of adult patients on dialysis, including both incident and prevalent dialysis patients. Akebia Therapeutics 's estimated revenue per employee is $ 590,452 Akebia Therapeutics 's total funding is $142.1M. Akebia Says Program Demonstrated Efficacy And Cardiovascular Safety Of Vadadustat . The decline versus the prior year period was driven by lower collaboration revenue consistent with the Company completing the INNO 2 VATE and PRO 2 TECT studies. It specializes in the development of digital platforms for digital media companies, cloud and managed service providers, financial institutions, and telecommunications providers. Copyright 2020 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606. The Company's significant revenue growth reflects its strategic merger with Keryx Biopharmaceuticals, Inc. (Keryx) on December 12, 2018, whereby Keryx became Akebia's wholly owned subsidiary. Visit performance for information about the performance numbers displayed above. Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on … This compares to year-ago revenues of $100.80 million. Nov. 5, 2020 8:06 AM ET | About: Akebia Therapeutics, Inc. (AKBA) | By: Pranav Ghumatkar, SA News Editor Les Charges D'Exploitation. Conference Call Akebia will host a conference call at 9:00 a.m. Eastern Time today, Thursday, November 5th, to discuss its third quarter financial results and recent business highlights. An online archive of the conference call can be accessed via the Investors section of the Company's website at http://ir.akebia.com. The decline versus the prior year period was driven by lower collaboration revenue consistent with the Company completing the INNO 2 VATE studies and nearing completion of the PRO 2 TECT studies. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. Recherchez les prévisions de marché, les actualités financières et du marché concernant AKBA. Zacks Ranks stocks can, and often do, change throughout the month. NASDAQ data is at least 15 minutes delayed. Bénéfice Avant Impôts. Following the downgrade, the consensus from eight analysts covering Akebia Therapeutics is for revenues of US$240m in 2021, implying a concerning 22% decline in … The institutional Ownership of the shares of 72.2 stands at 0.80%, this figure is decreased -8.13 in the last six months. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.41% per year. earnings-and-revenue-growth. Akebia Therapeutics, Inc. … Akebia Therapeutics, Inc. () Stock Market info Recommendations: Buy or sell Akebia Therapeutics stock? 245 First Street, Suite 1400 In Japan, vadadustat is approved as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients. VIEW ALL NEWS. The results fell short of Wall Street expectations. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. "We recently completed our pre-NDA meeting with the FDA. Découvrez le chiffre d’affaires, le coût d’exploitation, ainsi que les bénéfices ou les pertes réalisés au cours du dernier exercice fiscal.
2020 akebia therapeutics revenue